Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach, which is investigated for the treatment of treatment-resistant depression.
Brand Name : GH001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2023
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : RA Capital
Deal Size : $125.0 million
Deal Type : Series B Financing
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
Details : GH Research will use the proceeds to support further clinical development of GH001 (5-MeO-DMT) in Treatment-Resistant Depression (TRD) and to advance GH001 into further clinical development in additional psychiatric and neurological disorders.
Brand Name : GH001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : RA Capital
Deal Size : $125.0 million
Deal Type : Series B Financing
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GH001 has the potential to offer an ultra-rapid clearance of symptoms with long-term sustained remission after a single administration session. In the completed Phase 1 healthy volunteer study (GH001-HV-101), GH001 was safe and well-tolerated at the inve...
Brand Name : GH001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 19, 2020
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?